RGS2 and ovarian carcinoma: A recent research revealed the modulation of RGS2 expression by DNA methylation and histone deacetylation particularly in the chemoresistant ovarian cancer cells, and as a result, the expression of RGS2 is declined in the ovarian cancer cells resistant to drugs [24].